GlycoMimetics Inc (NASDAQ:GLYC) Director Daniel M. Junius acquired 10,000 shares of GlycoMimetics stock in a transaction that occurred on Tuesday, August 13th. The shares were purchased at an average price of $3.18 per share, with a total value of $31,800.00. Following the purchase, the director now owns 18,000 shares in the company, valued at $57,240. The purchase was disclosed in a legal filing with the SEC, which is available through this link.

NASDAQ:GLYC traded up $0.14 during trading hours on Thursday, hitting $3.05. 1,742,000 shares of the company were exchanged, compared to its average volume of 470,561. The stock has a market cap of $125.90 million, a PE ratio of -2.58 and a beta of 2.45. GlycoMimetics Inc has a 52-week low of $2.64 and a 52-week high of $16.35. The company has a debt-to-equity ratio of 0.02, a current ratio of 17.54 and a quick ratio of 17.54. The company’s 50 day moving average is $9.44.

GlycoMimetics (NASDAQ:GLYC) last released its earnings results on Thursday, August 1st. The biotechnology company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.01). As a group, equities research analysts predict that GlycoMimetics Inc will post -1.49 EPS for the current year.

GLYC has been the subject of several recent analyst reports. BidaskClub lowered shares of GlycoMimetics from a “hold” rating to a “sell” rating in a research note on Wednesday, July 24th. Jefferies Financial Group lowered shares of GlycoMimetics from a “buy” rating to a “hold” rating in a research note on Monday, August 5th. Cowen reiterated a “buy” rating on shares of GlycoMimetics in a research note on Friday, May 3rd. SunTrust Banks lowered shares of GlycoMimetics from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $23.00 to $5.00 in a research note on Monday, August 5th. Finally, HC Wainwright reduced their price objective on shares of GlycoMimetics from $23.00 to $18.00 and set a “buy” rating for the company in a research note on Monday, August 5th. One analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the stock. GlycoMimetics presently has an average rating of “Hold” and an average price target of $13.45.

Large investors have recently added to or reduced their stakes in the business. Invesco Ltd. acquired a new position in shares of GlycoMimetics during the 2nd quarter worth $56,816,000. AXA raised its stake in shares of GlycoMimetics by 0.6% during the 2nd quarter. AXA now owns 930,551 shares of the biotechnology company’s stock worth $11,092,000 after buying an additional 5,407 shares during the last quarter. Northern Trust Corp raised its stake in shares of GlycoMimetics by 1.8% during the 2nd quarter. Northern Trust Corp now owns 467,600 shares of the biotechnology company’s stock worth $5,574,000 after buying an additional 8,240 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of GlycoMimetics by 4.0% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 81,784 shares of the biotechnology company’s stock worth $975,000 after buying an additional 3,157 shares during the last quarter. Finally, Asymmetry Capital Management L.P. raised its stake in shares of GlycoMimetics by 263.5% during the 2nd quarter. Asymmetry Capital Management L.P. now owns 498,023 shares of the biotechnology company’s stock worth $5,936,000 after buying an additional 361,033 shares during the last quarter.

GlycoMimetics Company Profile

GlycoMimetics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and is in a Phase III clinical trial, conducted by its strategic collaboration with Pfizer Inc It is also developing uproleselan, an E-selectin antagonist that is evaluated in a Phase I/II clinical trial as a potential treatment for acute myeloid leukemia (AML), as well as Phase III trial to treat relapsed/refractory AML.

Further Reading: Understanding Price to Earnings Ratio (PE)

Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.